982352 Stock Overview
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
AstraZeneca PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£135.28 |
| 52 Week High | UK£135.75 |
| 52 Week Low | UK£113.35 |
| Beta | 0.19 |
| 1 Month Change | 15.74% |
| 3 Month Change | 15.98% |
| 1 Year Change | 0.11% |
| 3 Year Change | 42.40% |
| 5 Year Change | 74.78% |
| Change since IPO | 112.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| 982352 | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | 7.9% | 3.2% | 0.03% |
| 1Y | 0.1% | -11.8% | -3.3% |
Return vs Industry: 000982352 exceeded the Swiss Pharmaceuticals industry which returned -11.4% over the past year.
Return vs Market: 000982352 exceeded the Swiss Market which returned -2.5% over the past year.
Price Volatility
| 982352 volatility | |
|---|---|
| 982352 Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 3.3% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 2.0% |
Stable Share Price: 000982352 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 000982352's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 89,900 | Pascal Soriot | www.astrazeneca.com |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease.
AstraZeneca PLC Fundamentals Summary
| 982352 fundamental statistics | |
|---|---|
| Market cap | CHF212.83b |
| Earnings (TTM) | CHF5.78b |
| Revenue (TTM) | CHF43.44b |
36.8x
P/E Ratio4.9x
P/S RatioIs 982352 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 982352 income statement (TTM) | |
|---|---|
| Revenue | US$47.61b |
| Cost of Revenue | US$8.33b |
| Gross Profit | US$39.28b |
| Other Expenses | US$32.95b |
| Earnings | US$6.33b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 25, 2024
| Earnings per share (EPS) | 4.08 |
| Gross Margin | 82.50% |
| Net Profit Margin | 13.30% |
| Debt/Equity Ratio | 89.2% |
How did 982352 perform over the long term?
See historical performance and comparison